Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 3:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: FDA-Approved Treatment Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study

NCT00445913
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Diabetes-suppressive dendritic cell vaccine, control dendritic cells
Biological
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 14, 2016 · Synced Sep 28, 2026, 3:48 AM EDT
Completed Phase 4 Interventional Results available

Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue

NCT03621761
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Telephone-based Cognitive Behavioral Therapy, Modafinil
Behavioral · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Ann Arbor, Michigan • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 26, 2022 · Synced Sep 28, 2026, 3:48 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

NCT04074967
View directory record Official record
Conditions
Renal Cell Carcinoma, Melanoma, Solid Tumor, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
Phase Ib ARRY-614 + nivolumab, Phase Ib ARRY-614 + nivolumab+ipilimumab, Phase II ARRY-614 + nivolumab, Phase II ARRY-614 + nivolumab+ipilimumab (melanoma), Phase II ARRY-614 + nivolumab+ipilimumab (RCC)
Drug
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 28, 2026, 3:48 AM EDT
Completed Phase 4 Interventional Results available

Alcohol Research Consortium in HIV-Intervention Research Arm

NCT02938377
View directory record Official record
Conditions
HIV Positive, Alcohol Use
Interventions
Computerized Brief Intervention (CBI), CBT4CBT, Recommendation and Counseling for Alcohol Pharmacotherapy
Behavioral · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
4,985 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Birmingham, Alabama • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 28, 2026, 3:48 AM EDT
Completed No phase listed Observational

Studying Pathways of Resistance in KRAS-driven Cancers

NCT05272423
View directory record Official record
Conditions
KRAS P.G12C
Interventions
FoundationOne® Liquid CDx
Diagnostic Test
Lead sponsor
Addario Lung Cancer Medical Institute
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 28, 2026, 3:48 AM EDT
Not listed Early Phase 1 Interventional

Photobiomodulation to Improve Cognition in TBI, With fMRI

NCT04230577
View directory record Official record
Conditions
Traumatic Brain Injury, Closed Head Injury, Cognitive Dysfunction
Interventions
Real LED Intervention, Sham LED Intervention
Device
Lead sponsor
Boston VA Research Institute, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Sep 28, 2026, 3:48 AM EDT
Completed Not applicable Interventional Results available

An Efficacy and Safety Trial of Intranasal Ketorolac in Emergency Department Patients for the Treatment of Acute Pain

NCT01471639
View directory record Official record
Conditions
Other Acute Pain
Interventions
intranasal ketorolac
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 28, 2026, 3:48 AM EDT
Completed Phase 2 Interventional

BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study

NCT02481245
View directory record Official record
Conditions
Bipolar Disorder, Depressive Episode
Interventions
Bezafibrate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 28, 2026, 3:48 AM EDT
Completed Phase 2 Interventional Results available

Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP)

NCT03975153
View directory record Official record
Conditions
Pityriasis Rubra Pilaris
Interventions
guselkumab
Biological
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Sep 28, 2026, 3:48 AM EDT
Completed No phase listed Observational Results available

Phase IV Study of FDA Approved, Once-Daily GRALISE™(Gabapentin) Tablets for the Treatment of Postherpetic Neuralgia

NCT01426230
View directory record Official record
Conditions
Post Herpetic Neuralgia
Interventions
Not listed
Lead sponsor
Depomed
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
37
States / cities
Mobile, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Sep 28, 2026, 3:48 AM EDT
Enrolling by invitation Phase 4 Interventional

Quality Improvement and Practice Based Research in Neurology Using the EMR

NCT02670161
View directory record Official record
Conditions
Brain Tumors, Epilepsy, Migraine, Mild Cognitive Impairment, Concussion, Multiple Sclerosis, Neuropathy, Parkinson's, Restless Legs Syndrome, Stroke
Interventions
Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 100 Years
Enrollment
3,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Sep 28, 2026, 3:48 AM EDT
Completed Phase 4 Interventional Results available

Envarsus in Delayed Graft Function (E-DGF)

NCT03864926
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Envarsus XR, Tacrolimus
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Sep 28, 2026, 3:48 AM EDT
Recruiting Phase 2 Interventional

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

NCT02693535
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
Interventions
Sunitinib (CLOSED TO ENROLLMENT), Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT), Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT), Olaparib (CLOSED TO ENROLLMENT), Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT), Abemaciclib (CLOSED TO ENROLLMENT), Talazoparib (CLOSED TO ENROLLMENT), Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT), Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT), Futibatinib, Dabrafenib plus Trametinib, Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
Drug
Lead sponsor
American Society of Clinical Oncology
Other
Eligibility
12 Years and older
Enrollment
4,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
174
States / cities
Birmingham, Alabama • Phoenix, Arizona • Auburn, California + 137 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 28, 2026, 3:48 AM EDT
Recruiting Phase 4 Interventional

Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency

NCT07502378
View directory record Official record
Conditions
Ocular Surface Disease, Neurotrophic Keratopathy Stage 1
Interventions
Patients will receive topical Acoltremon 0.003% ophthalmic solution BID in both eyes over an 8 week period., Alternative would be patient exiting the trial and starting on tears or other standard of care.
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 28, 2026, 3:48 AM EDT
Active, not recruiting Phase 4 Interventional

Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions

NCT06801015
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide, Tirzepatide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Sep 28, 2026, 3:48 AM EDT
Recruiting No phase listed Observational

Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance

NCT07131631
View directory record Official record
Conditions
Heart Failure and Reduced Ejection Fraction, Functional Mitral Regurgitation
Interventions
Cardiac MRI
Diagnostic Test
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Minneapolis, Minnesota • Charlotte, North Carolina • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 28, 2026, 3:48 AM EDT
Terminated Phase 2 Interventional Results available

Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)

NCT00252239
View directory record Official record
Conditions
Stroke
Interventions
tenecteplase, tissue plasminogen activator, tPA
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
9
States / cities
San Diego, California • Englewood, Colorado • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 28, 2026, 3:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Hepatic Impairment Study

NCT01231529
View directory record Official record
Conditions
Healthy Subjects, Hepatic Impairment, Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK1349572
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Sep 28, 2026, 3:48 AM EDT
Completed Early Phase 1 Interventional

Effects Zulresso on Postpartum Psychosis

NCT05314153
View directory record Official record
Conditions
Postpartum Psychosis
Interventions
Brexanolone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2024 · Synced Sep 28, 2026, 3:48 AM EDT
Completed Not applicable Interventional Results available

FDG-PET/CT in the Evaluation of Patients With Suspected Cholecystitis

NCT00590395
View directory record Official record
Conditions
Cholecystitis
Interventions
18FDG (an FDA-approved radiopharmaceutical)
Drug
Lead sponsor
Alan D. Waxman, M.D.
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Sep 28, 2026, 3:48 AM EDT
Completed Phase 4 Interventional Results available

Iron Indices and Intravenous Ferumoxytol: Time to Steady State

NCT01148745
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
ferumoxytol
Drug
Lead sponsor
Dialysis Clinic, Inc.
Industry
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
North Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Sep 28, 2026, 3:48 AM EDT
Completed Phase 1 Interventional

Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients

NCT00437372
View directory record Official record
Conditions
Cancer, Head and Neck Cancer, Pelvic Cancer, Nervous System Neoplasms, Thoracic Neoplasms
Interventions
Sunitinib, External Beam Radiation Therapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 28, 2026, 3:48 AM EDT
Completed Not applicable Interventional

Remote Monitoring and Home-based Health Care for Treatment of Bone Marrow Transplant Patients

NCT05662631
View directory record Official record
Conditions
Bone Marrow Transplant
Interventions
BioIntellisense BioSticker
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Sep 28, 2026, 3:48 AM EDT
Completed Phase 2 Interventional

Symptom-specific TMS Targets for Depression and Anxiety

NCT04604210
View directory record Official record
Conditions
Depression, Anxiety, Major Depressive Disorder
Interventions
Transcranial magnetic stimulation
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Sep 28, 2026, 3:48 AM EDT